Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Forte Biosciences, Inc.

Market Cap 425M 367M 338M 317M 594M 40.41B 603M 4B 1.56B 19.67B 1.6B 1.56B 68.11B P/E Ratio 2026 *
-4.24x
P/E Ratio 2027 * -4.09x
Enterprise Value 425M 367M 338M 317M 594M 40.41B 603M 4B 1.56B 19.67B 1.6B 1.56B 68.11B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day+1.84%
1 week+7.32%
Current month-7.03%
1 month-27.01%
3 months-34.62%
6 months-17.03%
Current year-34.98%
1 week 15.51
Extreme 15.51
18.49
1 month 15.51
Extreme 15.51
25.01
Current year 15.51
Extreme 15.51
35.8
1 year 9.1
Extreme 9.1
35.8
3 years 4.11
Extreme 4.11
35.8
5 years 4.11
Extreme 4.11
1,045.25
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
05-29Free

Director

18,353 0.0896%
05-29Free

Director

18,353 0.0896%
05-29Free

Director

18,353 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
+1.47%+7.32%+41.39%-30.47% 425M
+1.03%+2.30%+54.92%+111.78% 55.58B
+2.72%+3.06%+53.28%+47.85% 43.47B
+0.85%+2.71%-13.77%-17.60% 22.64B
+1.21%+3.95%+1.10%+402.28% 20.96B
+3.81%-4.13%+16.62%-30.70% 15.79B
+0.15%+0.50%+9.10%-40.04% 15.3B
-0.58%+0.91%+27.29%+178.58% 13.45B
+5.27%+6.41%+21.05% - 11.74B
+1.61%+1.17%+90.79%+212.97% 10.96B
Average +1.80%+0.66%+30.18%+92.74% 21.03B
Weighted average by Cap. +1.70%+1.61%+33.80%+100.48%

Financials

2026 *2027 *
Net sales - -
Net income -95.54M -82.52M -76.04M -71.18M -133M -9.08B -135M -898M -350M -4.42B -359M -351M -15.3B -130M -113M -104M -97.17M -182M -12.4B -185M -1.23B -478M -6.03B -490M -479M -20.89B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
12/06/26 17.67 $ +1.55% 105,209
11/06/26 17.40 $ +3.45% 172,225
10/06/26 16.82 $ -1.06% 254,561
09/06/26 17.00 $ +8.49% 415,549
08/06/26 15.67 $ -5.15% 248,923
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.40USD
Average target price
63.75USD
Spread / Average Target
+266.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!